CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: TRUB2 (ImmuneEditome ID:26995)

1. Gene summary of enriched editing regions for TRUB2

check button Gene summary
Gene informationGene symbol

TRUB2

Gene ID

26995

GeneSynonymsCLONE24922
GeneCytomap

9q34.11

GeneTypeprotein-coding
GeneDescriptionpseudouridylate synthase TRUB2, mitochondrial|TruB pseudouridine (psi) synthase family member 2|TruB pseudouridine (psi) synthase homolog 2|mitochondrial mRNA pseudouridine synthase TRUB2|probable tRNA pseudouridine synthase 2|psi55 synthase TRUB2|tRNA pseudouridine 55 synthase TRUB2|truB pseudouridine synthase homolog 2
GeneModificationdate20230329
UniprotIDO95900;A0A024R886
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr9:128305391-128308898:-ENST00000372890.5ENSG00000167112.9TRUB2UTR3AluY,AluSx1,AluSz,AluJo,AluSx,AluSx3,MLT2D,AluYh3chr9:128305391-128308898:-.alignment


Top

2. Tumor-specific enriched editing regions for TRUB2


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr9:128305391-128308898:-COADEER1.0650e-02image
ENSG00000167112.9,TRUB2COADEAG2.0338e-02image
chr9:128305391-128308898:-HNSCEER2.2844e-08image
ENSG00000167112.9,TRUB2HNSCEAG4.5649e-08image
chr9:128305391-128308898:-KIRCEER4.7548e-02image
chr9:128305391-128308898:-KIRPEER1.4310e-05image
ENSG00000167112.9,TRUB2KIRPEAG1.8917e-05image
chr9:128305391-128308898:-LUADEER5.4947e-03image
ENSG00000167112.9,TRUB2LUADEAG3.8037e-02image
chr9:128305391-128308898:-PRADEER4.4406e-05image
ENSG00000167112.9,TRUB2PRADEAG4.6374e-05image
chr9:128305391-128308898:-UCECEER2.8462e-02image
ENSG00000167112.9,TRUB2UCECEAG9.6254e-03image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
chr9:128305391-128308898:-THCAPathEER2.3829e-032.4843e-020.1002image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
chr9:128305391-128308898:-LAMLEER3.7367e-024.2501e-021.5380e+01image

Top

3. Enriched editing regions and immune related genes for TRUB2


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr9:128305391-128308898:-COADEERENSG00000176148,TCP11L10.26062.1959e-036.4474e-130.4303imageNCNBP;CSTF2T;DICER1;EIF4A3;ELAVL1;FBL;FMR1;FUS;HNRNPC;IGF2BP1;IGF2BP2;IGF2BP3;LIN28A;MOV10;NOP56;NOP58;SMNDC1;TARDBP;U2AF2;UPF1NANeutrophilsGSVA_HALLMARK_DNA_REPAIR
chr9:128305391-128308898:-COADEERENSG00000152104,PTPN140.25872.1991e-033.6457e-120.4173imageNACIN1;CNBP;CSTF2T;DICER1;EIF4A3;ELAVL1;FBL;FMR1;FUS;HNRNPC;IGF2BP1;IGF2BP2;IGF2BP3;LIN28A;MOV10;MSI1;NOP56;NOP58;SMNDC1;TARDBP;U2AF2;UPF1NANeutrophilsGSVA_HALLMARK_DNA_REPAIR
chr9:128305391-128308898:-COADEERENSG00000180263,FGD60.23945.8400e-033.2031e-110.4001imageNACIN1;CNBP;CSTF2T;DICER1;EIF4A3;ELAVL1;FBL;FMR1;FUS;HNRNPC;IGF2BP1;IGF2BP2;IGF2BP3;LIN28A;MOV10;MSI1;NOP56;NOP58;SMNDC1;TARDBP;U2AF2;UPF1NANeutrophilsGSVA_HALLMARK_PEROXISOME
chr9:128305391-128308898:-STADEERENSG00000173611,SCAI-0.45703.1314e-149.8887e-16-0.4136imageNACIN1;CNBP;CSTF2T;DICER1;EIF4A3;ELAVL1;FBL;FMR1;FUS;HNRNPC;IGF2BP1;IGF2BP2;IGF2BP3;MOV10;MSI1;NOP56;NOP58;SMNDC1;TARDBP;U2AF2;UPF1NANeutrophilsGSVA_HALLMARK_XENOBIOTIC_METABOLISM
chr9:128305391-128308898:-DLBCEERENSG00000115866,DARS0.50053.2128e-027.5157e-040.4699imageNACIN1;CNBP;CSTF2T;DICER1;EIF4A3;ELAVL1;FBL;FMR1;FUS;HNRNPC;IGF2BP1;IGF2BP2;IGF2BP3;LIN28A;MOV10;MSI1;NOP56;NOP58;SMNDC1;TARDBP;U2AF2;UPF1NAT_cells_CD4_memory_activatedGSVA_HALLMARK_MITOTIC_SPINDLE
chr9:128305391-128308898:-DLBCEERENSG00000169032,MAP2K10.52123.2273e-029.4377e-050.5335imageNACIN1;CNBP;CSTF2T;DICER1;EIF4A3;ELAVL1;FBL;FMR1;FUS;HNRNPC;IGF2BP1;IGF2BP2;IGF2BP3;LIN28A;MOV10;MSI1;NOP56;NOP58;SMNDC1;TARDBP;U2AF2;UPF1MAP2K1T_cells_CD4_memory_restingGSVA_HALLMARK_UV_RESPONSE_DN
chr9:128305391-128308898:-DLBCEERENSG00000187778,MCRS1-0.53203.5864e-022.7005e-04-0.5028imageNACIN1;CNBP;CSTF2T;DICER1;EIF4A3;ELAVL1;FBL;FMR1;FUS;HNRNPC;IGF2BP1;IGF2BP2;IGF2BP3;MOV10;NOP56;NOP58;SMNDC1;TARDBP;U2AF2;UPF1NAMacrophages_M1GSVA_HALLMARK_IL6_JAK_STAT3_SIGNALING
chr9:128305391-128308898:-DLBCEERENSG00000278133,RP11-196G11.5-0.52344.7174e-022.0903e-03-0.4334imageNDICER1;EIF4A3;ELAVL1;FBL;FMR1;FUS;HNRNPC;IGF2BP1;IGF2BP2;IGF2BP3;MOV10;NOP56;NOP58;SMNDC1;TARDBP;U2AF2;UPF1NAPlasma_cellsGSVA_HALLMARK_GLYCOLYSIS
chr9:128305391-128308898:-SKCMEERENSG00000167112,TRUB2-0.42072.2435e-165.4033e-19-0.4001imageNACIN1;CNBP;CSTF2T;DICER1;EIF4A3;ELAVL1;FBL;FMR1;FUS;HNRNPC;IGF2BP1;IGF2BP2;IGF2BP3;MOV10;NOP56;NOP58;SMNDC1;TARDBP;U2AF2;UPF1NAT_cells_CD8GSVA_HALLMARK_MYC_TARGETS_V2
chr9:128305391-128308898:-UVMEERENSG00000269044,CTC-429P9.3-0.49187.9719e-041.5699e-04-0.4127imageNCSTF2T;EIF4A3;ELAVL1;FBL;FMR1;FUS;HNRNPC;IGF2BP1;IGF2BP2;IGF2BP3;LIN28A;MOV10;NOP56;NOP58;SMNDC1;TARDBP;U2AF2;UPF1NAT_cells_CD4_memory_restingGSVA_HALLMARK_MYOGENESIS

More results



Top

4. Enriched editing regions and immune related splicing for TRUB2


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
ENSG00000167112.9,TRUB2
COADEAGMEXENSG00000100591.3chr1477462159:77462242:77462641:77462759:77465538:77465667:77468082:774681840.24012.6360e-022.2896e-150.4692imageNACIN1;ADAR;AIFM1;BCCIP;BUD13;CAPRIN1;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LARP7;LIN28;LIN28B;LSM11;MOV10;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RNF219;RTCB;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184NANeutrophilsGSVA_HALLMARK_UV_RESPONSE_DN
ENSG00000167112.9,TRUB2
ESCAEAGIRENSG00000006015.13chr1918588994:18590933:18592088:18592336-0.30251.0670e-023.2685e-06-0.4184imageNACIN1;ADAR;AIFM1;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;EIF4A3;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP4B;LARP7;LIN28;LIN28B;LSM11;MOV10;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM27;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YWHAG;ZNF184NAB_cells_naiveGSVA_HALLMARK_HYPOXIA
chr9:128305391-128308898:-
ESCAEERESENSG00000165949.8chr1494110761:94110797:94111624:94111773:94114850:94114880-0.37316.7196e-031.1639e-07-0.4029imageNCSTF2T;EIF4A3;ELAVL1;FBL;FUS;HNRNPC;IGF2BP2;LIN28A;NOP56;NOP58;TARDBP;U2AF2IFI27T_cells_CD8GSVA_HALLMARK_BILE_ACID_METABOLISM
chr9:128305391-128308898:-
ESCAEERIRENSG00000006015.13chr1918588994:18590933:18592088:18592336-0.30348.7699e-033.2685e-06-0.4184imageNACIN1;CNBP;CSTF2T;EIF4A3;ELAVL1;FBL;FMR1;FUS;HNRNPC;IGF2BP2;IGF2BP3;MOV10;NOP56;NOP58;SMNDC1;TARDBP;U2AF2;UPF1NAB_cells_naiveGSVA_HALLMARK_HYPOXIA
ENSG00000167112.9,TRUB2
ESCAEAGESENSG00000165949.8chr1494110761:94110797:94111624:94111773:94114850:94114880-0.37686.6525e-031.0067e-07-0.4048imageNCSTF2T;DGCR8;DHX9;DKC1;EIF4A3;ELAVL1;EWSR1;FBL;FUS;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPU;IGF2BP2;KHSRP;LIN28B;NOP56;NOP58;NUMA1;PTBP1;RBFOX2;RBM10;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;U2AF2;XRN2;ZNF184IFI27T_cells_CD8GSVA_HALLMARK_BILE_ACID_METABOLISM
chr9:128305391-128308898:-
THYMEERMEXENSG00000154553.9chr4185506521:185506652:185514702:185514890:185525019:185525171:185535341:185535466-0.33081.2721e-023.8352e-05-0.4196imageNACIN1;CNBP;CSTF2T;EIF4A3;ELAVL1;FBL;FMR1;FUS;HNRNPC;IGF2BP1;IGF2BP2;IGF2BP3;LIN28A;MOV10;NOP56;NOP58;TARDBP;U2AF2;UPF1NAT_cells_follicular_helperGSVA_HALLMARK_PROTEIN_SECRETION
chr9:128305391-128308898:-
THYMEERA3ENSG00000188493.10chr1940743904:40743975:40740860:40741008:40740860:40742770-0.34254.8796e-032.2374e-05-0.4142imageNCNBP;CSTF2T;DICER1;EIF4A3;ELAVL1;FBL;FMR1;FUS;HNRNPC;IGF2BP1;IGF2BP2;IGF2BP3;LIN28A;MOV10;MSI1;NOP56;NOP58;SMNDC1;TARDBP;U2AF2;UPF1NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_PROTEIN_SECRETION
chr9:128305391-128308898:-
THYMEERESENSG00000140995.12chr1689948802:89948814:89949419:89949513:89954242:899543760.44067.1809e-046.8752e-060.4177imageNCNBP;CSTF2T;DICER1;EIF4A3;ELAVL1;FBL;FMR1;FUS;HNRNPC;IGF2BP1;IGF2BP2;IGF2BP3;LIN28A;MOV10;NOP56;NOP58;SMNDC1;TARDBP;U2AF2;UPF1NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_MYC_TARGETS_V2
chr9:128305391-128308898:-
THYMEERIRENSG00000198807.8chr1436657567:36657900:36659337:36659537-0.26963.1384e-025.6764e-06-0.4446imageNCNBP;CSTF2T;DICER1;EIF4A3;ELAVL1;FBL;FMR1;FUS;HNRNPC;IGF2BP1;IGF2BP2;IGF2BP3;MOV10;NOP56;NOP58;U2AF2;UPF1NAMonocytesGSVA_HALLMARK_UV_RESPONSE_DN
ENSG00000167112.9,TRUB2
THYMEAGA3ENSG00000188493.10chr1940743904:40743975:40740860:40741008:40740860:40742770-0.34194.9951e-032.7160e-05-0.4103imageNADAR;AIFM1;BCCIP;BUD13;CAPRIN1;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LARP7;LIN28;LIN28B;LSM11;MOV10;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM27;RNF219;RTCB;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;ZNF184NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_PROTEIN_SECRETION

More results



Top

5. Enriched editing regions and immune infiltration for TRUB2


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr9:128305391-128308898:-BLCAEERT_cells_regulatory_(Tregs)1.8947e-03-0.1641image
ENSG00000167112.9,TRUB2BLCAEAGT_cells_regulatory_(Tregs)1.9747e-03-0.1634image
chr9:128305391-128308898:-BRCAEERMacrophages_M13.4702e-040.1095image
ENSG00000167112.9,TRUB2BRCAEAGMacrophages_M12.4008e-040.1124image
chr9:128305391-128308898:-COADEERNeutrophils3.3133e-030.1833image
ENSG00000167112.9,TRUB2COADEAGNeutrophils4.0954e-030.1792image
chr9:128305391-128308898:-DLBCEERMast_cells_resting1.7030e-020.3429image
ENSG00000167112.9,TRUB2DLBCEAGMast_cells_resting1.7030e-020.3429image
chr9:128305391-128308898:-ESCAEERT_cells_CD86.9076e-040.2647image
ENSG00000167112.9,TRUB2ESCAEAGT_cells_CD87.9839e-040.2617image
chr9:128305391-128308898:-GBMEERMast_cells_resting5.8460e-030.2163image
ENSG00000167112.9,TRUB2GBMEAGMast_cells_resting4.7904e-030.2213image
chr9:128305391-128308898:-HNSCEERT_cells_regulatory_(Tregs)3.2507e-03-0.1339image
ENSG00000167112.9,TRUB2HNSCEAGT_cells_regulatory_(Tregs)2.0959e-03-0.1399image
chr9:128305391-128308898:-KICHEEREosinophils3.2914e-020.2670image
ENSG00000167112.9,TRUB2KICHEAGEosinophils3.2914e-020.2670image
chr9:128305391-128308898:-KIRCEERMacrophages_M13.1866e-04-0.1900image
ENSG00000167112.9,TRUB2KIRCEAGMacrophages_M11.6295e-04-0.1988image
chr9:128305391-128308898:-KIRPEERT_cells_CD4_memory_activated1.1595e-040.2275image
ENSG00000167112.9,TRUB2KIRPEAGNK_cells_activated1.1078e-04-0.2282image
chr9:128305391-128308898:-LAMLEERMacrophages_M02.8333e-020.2193image
ENSG00000167112.9,TRUB2LAMLEAGMacrophages_M02.3889e-020.2236image
chr9:128305391-128308898:-LGGEEREosinophils7.3875e-040.1466image
ENSG00000167112.9,TRUB2LGGEAGEosinophils5.1909e-030.1215image
chr9:128305391-128308898:-LIHCEERMacrophages_M11.4412e-020.1289image
ENSG00000167112.9,TRUB2LIHCEAGMacrophages_M11.7921e-020.1247image
chr9:128305391-128308898:-LUADEERNK_cells_resting3.9195e-020.1025image
ENSG00000167112.9,TRUB2LUADEAGNK_cells_resting1.3094e-020.1222image
chr9:128305391-128308898:-LUSCEERDendritic_cells_resting6.4047e-03-0.1305image
ENSG00000167112.9,TRUB2LUSCEAGDendritic_cells_resting1.0549e-02-0.1225image
chr9:128305391-128308898:-MESOEERT_cells_CD81.1591e-020.2882image
ENSG00000167112.9,TRUB2MESOEAGT_cells_follicular_helper4.3461e-020.2323image
chr9:128305391-128308898:-OVEERT_cells_CD82.0087e-050.2488image
ENSG00000167112.9,TRUB2OVEAGT_cells_CD82.3248e-050.2470image
ENSG00000167112.9,TRUB2PAADEAGT_cells_CD84.9650e-02-0.1590image
chr9:128305391-128308898:-PCPGEERT_cells_CD4_memory_resting4.5020e-02-0.1488image
ENSG00000167112.9,TRUB2PCPGEAGT_cells_CD4_memory_resting3.3709e-02-0.1575image
chr9:128305391-128308898:-PRADEERDendritic_cells_activated2.7552e-180.3772image
ENSG00000167112.9,TRUB2PRADEAGDendritic_cells_activated1.4196e-180.3802image
chr9:128305391-128308898:-SARCEERT_cells_regulatory_(Tregs)2.3536e-02-0.1450image
chr9:128305391-128308898:-SKCMEERT_cells_CD81.6670e-060.2219image
ENSG00000167112.9,TRUB2SKCMEAGT_cells_CD81.3828e-050.2018image
chr9:128305391-128308898:-STADEERDendritic_cells_activated3.8491e-040.1898image
ENSG00000167112.9,TRUB2STADEAGDendritic_cells_activated2.2218e-040.1973image
chr9:128305391-128308898:-THCAEERNK_cells_activated1.1897e-04-0.1709image
ENSG00000167112.9,TRUB2THCAEAGNK_cells_activated7.9722e-04-0.1491image
chr9:128305391-128308898:-THYMEERNK_cells_activated1.1350e-040.3479image
ENSG00000167112.9,TRUB2THYMEAGNK_cells_activated2.3683e-040.3323image
chr9:128305391-128308898:-UCECEERMacrophages_M02.2412e-020.1730image
chr9:128305391-128308898:-UCSEERPlasma_cells1.0393e-030.4304image
ENSG00000167112.9,TRUB2UCSEAGPlasma_cells6.4111e-040.4461image


Top

6. Enriched editing regions and immune gene sets for TRUB2


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
ENSG00000167112.9,TRUB2BLCAEAG1.5937e-050.22652.4485e-050.22163.5295e-060.24297.1491e-080.2808image
chr9:128305391-128308898:-BLCAEER1.4995e-050.22722.3154e-050.22234.3491e-060.24074.1496e-080.2856image
chr9:128305391-128308898:-BRCAEER3.3216e-070.15589.0577e-050.11984.8108e-020.06061.2363e-090.1850image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
chr9:128305391-128308898:-ACCGSVA_HALLMARK_MYC_TARGETS_V2EER1.0830e-02-0.2927image
ENSG00000167112.9,TRUB2ACCGSVA_HALLMARK_PROTEIN_SECRETIONEAG3.5916e-030.3301image
ENSG00000167112.9,TRUB2BLCAGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEAG3.9852e-120.3568image
chr9:128305391-128308898:-BLCAGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEER3.7766e-120.3572image
chr9:128305391-128308898:-BRCAGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER4.9004e-160.2453image
ENSG00000167112.9,TRUB2BRCAGSVA_HALLMARK_GLYCOLYSISEAG1.0230e-160.2507image
chr9:128305391-128308898:-CESCGSVA_HALLMARK_COMPLEMENTEER4.6895e-040.2059image
ENSG00000167112.9,TRUB2CESCGSVA_HALLMARK_COMPLEMENTEAG3.2251e-050.2436image
ENSG00000167112.9,TRUB2COADGSVA_HALLMARK_INFLAMMATORY_RESPONSEEAG7.8281e-040.2090image
chr9:128305391-128308898:-COADGSVA_HALLMARK_INFLAMMATORY_RESPONSEEER5.0520e-040.2163image
chr9:128305391-128308898:-DLBCGSVA_HALLMARK_HYPOXIAEER7.8989e-030.3790image
ENSG00000167112.9,TRUB2DLBCGSVA_HALLMARK_HYPOXIAEAG7.8989e-030.3790image
chr9:128305391-128308898:-ESCAGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER1.2397e-030.2524image
ENSG00000167112.9,TRUB2ESCAGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG1.2595e-030.2520image
chr9:128305391-128308898:-GBMGSVA_HALLMARK_BILE_ACID_METABOLISMEER8.2377e-060.3433image
ENSG00000167112.9,TRUB2GBMGSVA_HALLMARK_BILE_ACID_METABOLISMEAG7.5980e-060.3446image
ENSG00000167112.9,TRUB2HNSCGSVA_HALLMARK_HYPOXIAEAG1.6948e-130.3276image
chr9:128305391-128308898:-HNSCGSVA_HALLMARK_HYPOXIAEER2.6253e-150.3500image
chr9:128305391-128308898:-KICHGSVA_HALLMARK_MYC_TARGETS_V2EER7.5107e-03-0.3312image
ENSG00000167112.9,TRUB2KICHGSVA_HALLMARK_MYC_TARGETS_V2EAG7.5107e-03-0.3312image
chr9:128305391-128308898:-KIRCGSVA_HALLMARK_KRAS_SIGNALING_DNEER2.3262e-020.1204image
ENSG00000167112.9,TRUB2KIRCGSVA_HALLMARK_KRAS_SIGNALING_DNEAG8.0521e-030.1404image
chr9:128305391-128308898:-KIRPGSVA_HALLMARK_DNA_REPAIREER3.3777e-03-0.1740image
ENSG00000167112.9,TRUB2KIRPGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEAG1.4188e-030.1891image
chr9:128305391-128308898:-LAMLGSVA_HALLMARK_PANCREAS_BETA_CELLSEER2.5713e-020.2230image
ENSG00000167112.9,TRUB2LGGGSVA_HALLMARK_MYC_TARGETS_V2EAG5.6638e-11-0.2801image
chr9:128305391-128308898:-LGGGSVA_HALLMARK_MYC_TARGETS_V2EER2.8603e-12-0.2980image
chr9:128305391-128308898:-LIHCGSVA_HALLMARK_UV_RESPONSE_DNEER4.0316e-090.3038image
ENSG00000167112.9,TRUB2LIHCGSVA_HALLMARK_UV_RESPONSE_DNEAG7.3486e-090.2988image
ENSG00000167112.9,TRUB2LUADGSVA_HALLMARK_TGF_BETA_SIGNALINGEAG5.0748e-030.1378image
chr9:128305391-128308898:-LUADGSVA_HALLMARK_TGF_BETA_SIGNALINGEER1.5431e-040.1870image
ENSG00000167112.9,TRUB2LUSCGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEAG2.3778e-040.1753image
chr9:128305391-128308898:-LUSCGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEER8.3703e-050.1875image
chr9:128305391-128308898:-MESOGSVA_HALLMARK_BILE_ACID_METABOLISMEER3.1919e-02-0.2464image
ENSG00000167112.9,TRUB2OVGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG1.3415e-060.2808image
chr9:128305391-128308898:-OVGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER9.7885e-070.2842image
ENSG00000167112.9,TRUB2PAADGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEAG2.1772e-030.2460image
chr9:128305391-128308898:-PAADGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEER1.2642e-030.2592image
chr9:128305391-128308898:-PRADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER3.7334e-080.2435image
ENSG00000167112.9,TRUB2PRADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG4.8401e-080.2415image
chr9:128305391-128308898:-READGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.4855e-030.3249image
ENSG00000167112.9,TRUB2READGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.4855e-030.3249image
chr9:128305391-128308898:-SARCGSVA_HALLMARK_HEME_METABOLISMEER7.1459e-040.2152image
ENSG00000167112.9,TRUB2SARCGSVA_HALLMARK_HEME_METABOLISMEAG1.0384e-030.2087image
chr9:128305391-128308898:-SKCMGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER5.7297e-080.2505image
ENSG00000167112.9,TRUB2SKCMGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG8.7733e-080.2471image
chr9:128305391-128308898:-STADGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER8.9172e-130.3717image
ENSG00000167112.9,TRUB2STADGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG1.8824e-120.3667image
ENSG00000167112.9,TRUB2THCAGSVA_HALLMARK_INFLAMMATORY_RESPONSEEAG2.9984e-090.2606image
chr9:128305391-128308898:-THCAGSVA_HALLMARK_INFLAMMATORY_RESPONSEEER1.3156e-120.3095image
chr9:128305391-128308898:-THYMGSVA_HALLMARK_MYC_TARGETS_V2EER1.0705e-05-0.3930image
ENSG00000167112.9,TRUB2THYMGSVA_HALLMARK_MYC_TARGETS_V2EAG2.0436e-05-0.3813image
ENSG00000167112.9,TRUB2UCECGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.2216e-030.2432image
chr9:128305391-128308898:-UCECGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.5797e-030.2271image
ENSG00000167112.9,TRUB2UCSGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEAG2.2472e-020.3073image
chr9:128305391-128308898:-UCSGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEER1.0551e-020.3422image
chr9:128305391-128308898:-UVMGSVA_HALLMARK_KRAS_SIGNALING_DNEER1.6960e-040.4108image
ENSG00000167112.9,TRUB2UVMGSVA_HALLMARK_KRAS_SIGNALING_DNEAG1.6960e-040.4108image


Top

7. Enriched editing regions and drugs for TRUB2


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000167112.9,TRUB2ACCAICAREAG1.0781e-03-0.3679image
chr9:128305391-128308898:-ACCGW843682XEER2.4229e-040.4118image
ENSG00000167112.9,TRUB2BLCAEHT.1864EAG5.1882e-070.2623image
chr9:128305391-128308898:-BLCAKIN001.135EER4.6236e-07-0.2634image
chr9:128305391-128308898:-BRCACGP.082996EER9.0637e-14-0.2259image
ENSG00000167112.9,TRUB2BRCACGP.082996EAG2.1008e-13-0.2225image
chr9:128305391-128308898:-CESCGSK.650394EER1.9612e-040.2189image
ENSG00000167112.9,TRUB2CESCGSK.650394EAG4.5990e-040.2062image
chr9:128305391-128308898:-CHOLBI.D1870EER4.5310e-020.3563image
ENSG00000167112.9,TRUB2CHOLElesclomolEAG4.2079e-020.3615image
chr9:128305391-128308898:-COADGW843682XEER1.2938e-040.2374image
ENSG00000167112.9,TRUB2COADLFM.A13EAG1.1345e-04-0.2394image
chr9:128305391-128308898:-DLBCElesclomolEER2.0083e-020.3346image
ENSG00000167112.9,TRUB2DLBCElesclomolEAG2.0083e-020.3346image
ENSG00000167112.9,TRUB2ESCACGP.60474EAG7.7964e-06-0.3442image
chr9:128305391-128308898:-ESCACGP.60474EER7.4840e-06-0.3448image
ENSG00000167112.9,TRUB2GBMGSK.650394EAG7.1588e-060.3455image
chr9:128305391-128308898:-GBMGSK.650394EER4.4239e-060.3528image
chr9:128305391-128308898:-HNSCBMS.708163EER1.5318e-08-0.2544image
ENSG00000167112.9,TRUB2HNSCBMS.708163EAG2.9090e-08-0.2496image
ENSG00000167112.9,TRUB2KICHAICAREAG7.2625e-04-0.4116image
chr9:128305391-128308898:-KICHAICAREER7.2625e-04-0.4116image
chr9:128305391-128308898:-KIRCBAY.61.3606EER3.7856e-050.2168image
ENSG00000167112.9,TRUB2KIRCBAY.61.3606EAG9.3183e-060.2328image
chr9:128305391-128308898:-KIRPGW843682XEER3.2752e-030.1745image
ENSG00000167112.9,TRUB2KIRPDMOGEAG5.0269e-03-0.1666image
chr9:128305391-128308898:-LAMLLenalidomideEER5.1017e-040.3413image
ENSG00000167112.9,TRUB2LAMLLenalidomideEAG1.4775e-030.3108image
ENSG00000167112.9,TRUB2LGGElesclomolEAG3.2472e-120.2970image
chr9:128305391-128308898:-LGGElesclomolEER9.6536e-150.3287image
chr9:128305391-128308898:-LIHCJNK.Inhibitor.VIIIEER4.3333e-09-0.3032image
ENSG00000167112.9,TRUB2LIHCJNK.Inhibitor.VIIIEAG5.2851e-09-0.3015image
ENSG00000167112.9,TRUB2LUADAZD7762EAG1.6284e-02-0.1183image
chr9:128305391-128308898:-LUADAICAREER1.8623e-02-0.1169image
chr9:128305391-128308898:-LUSCKU.55933EER3.0115e-03-0.1419image
ENSG00000167112.9,TRUB2LUSCAG.014699EAG1.8762e-03-0.1487image
ENSG00000167112.9,TRUB2MESOGDC0941EAG4.8745e-020.2269image
chr9:128305391-128308898:-MESOGDC0941EER2.3146e-020.2603image
chr9:128305391-128308898:-OVImatinibEER1.1616e-060.2824image
ENSG00000167112.9,TRUB2OVImatinibEAG1.0792e-060.2832image
chr9:128305391-128308898:-PAADBexaroteneEER2.5222e-02-0.1815image
ENSG00000167112.9,TRUB2PAADBexaroteneEAG9.2803e-03-0.2097image
ENSG00000167112.9,TRUB2PCPGEHT.1864EAG9.7135e-030.1912image
chr9:128305391-128308898:-PCPGEHT.1864EER1.0243e-020.1899image
ENSG00000167112.9,TRUB2PRADGW.441756EAG4.3150e-140.3297image
chr9:128305391-128308898:-PRADGW.441756EER3.3864e-140.3310image
chr9:128305391-128308898:-READBIRB.0796EER1.0476e-030.3345image
ENSG00000167112.9,TRUB2READBIRB.0796EAG1.0476e-030.3345image
ENSG00000167112.9,TRUB2SARCBleomycinEAG6.3416e-050.2532image
chr9:128305391-128308898:-SARCBleomycinEER2.6814e-040.2313image
chr9:128305391-128308898:-SKCMCI.1040EER3.5119e-06-0.2150image
ENSG00000167112.9,TRUB2SKCMCI.1040EAG3.0864e-06-0.2162image
chr9:128305391-128308898:-STADCI.1040EER2.6206e-08-0.2936image
ENSG00000167112.9,TRUB2STADCI.1040EAG1.1874e-06-0.2577image
chr9:128305391-128308898:-TGCTGSK.650394EER3.7339e-020.1808image
ENSG00000167112.9,TRUB2THCAMetforminEAG2.8440e-130.3179image
chr9:128305391-128308898:-THCAMetforminEER1.8108e-150.3449image
chr9:128305391-128308898:-THYMGW843682XEER2.2341e-060.4197image
ENSG00000167112.9,TRUB2THYMAxitinibEAG2.8846e-060.4155image
ENSG00000167112.9,TRUB2UCECJNK.Inhibitor.VIIIEAG1.5881e-03-0.2377image
chr9:128305391-128308898:-UCECAUY922EER2.1571e-030.2311image
chr9:128305391-128308898:-UCSCGP.60474EER1.4383e-04-0.4905image
ENSG00000167112.9,TRUB2UCSCGP.60474EAG7.7513e-05-0.5072image
ENSG00000167112.9,TRUB2UVMAZD7762EAG2.3805e-04-0.4022image
chr9:128305391-128308898:-UVMAZD7762EER2.3805e-04-0.4022image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType